Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Hidemasa SakaiSatoru IwashimaShinichiro SanoNaoe AkiyamaEiko NagataMasashi HarazakiTetuya FukuokaPublished in: Clinical drug investigation (2020)
The number of IVIG non-responders in the group with prednisolone administration was lower than that in the group without prednisolone administration. Secondary rescue infliximab therapy for IVIG non-responders resulted in a lower defervescence effect than the secondary rescue IVIG with prednisolone administration. Further prospective randomized studies are needed to identify factors useful for preventing IVIG non-responders and determine the optimal rescue therapy for preventing CAA.